The US Food and Drug Administration (FDA) has granted clearance for SIRPant Immunotherapeutics’ investigational new drug (IND) application enabling initiation of a first-in-human Phase I clinical trial of SIRPant-M to treat relapsed refractory non-Hodgkin lymphoma.
SIRPant plans to conduct this multi-centre study in the third quarter across five sites in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients with relapsed refractory non-Hodgkin lymphoma will be administered with SIRPant-M, an autologous SIRPαlow activated macrophage immunotherapy to treat aggressive tumours.
SIRPant R&D vice-president Nathanael McCurley said: “Leveraging recent findings in macrophage biology, we developed a first-in-class cell therapy, SIRPant-M, to initiate adaptive immune responses against cancerous cells without requiring prior cancer-associated antigen identification.
“SIRPant-M employs a proprietary cocktail, PhagoAct, to license macrophages to drive tumour neo-antigen-specific polyclonal T cell and antibody responses, thus targeting cancer cells through multiple avenues simultaneously.”
SIRPant-M also brings in long-lasting polyclonal immune memory against cancer by mobilising the cellular as well as humoral arms of the immune system.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company also plans to file a second IND for SIRPant-M to treat solid tumours, initially targeting head and neck cancers.
SIRPant president and CEO Robert Towarnicki said: “This initial study will enroll relapsed refractory non-Hodgkin lymphoma patients who are ineligible for or previously failed approved therapeutic regimens.”
